April 29, 2015
Amniox Medical Announces Expanded Health Plan Coverage
ATLANTA – April 29, 2015 – Amniox Medical, Inc., (“Amniox”, the “Company”), a leading developer and marketer of regenerative therapies processed from umbilical cord and amniotic membrane for wound care and reconstructive surgery, announced today the Company’s expanded payer coverage for Medicare patients administered by Novitas Solutions.
Novitas is a Part A and Part B Medicare Administrative Contractor that adjudicates facility and professional claims in jurisdictions spanning 11 states, including Arkansas, Colorado, Delaware, Louisiana, Maryland, Mississippi, New Mexico, New Jersey, Oklahoma, Pennsylvania, and Texas, as well as the District of Columbia. These jurisdictions cover approximately nine million lives and are responsible for more than 24% of total Medicare claims.
Thomas J. Dugan, CEO of Amniox, said, “We are extremely pleased with the significant increase in health plan coverage and validation by Medicare of our restorative therapies. Health plans perform a rigorous analysis before granting coverage and this approval is a testament to the benefits of our wound care solutions. Millions of additional Medicare patients will now enjoy access to this technology. In the meantime, pursuing increased coverage for other Medicare beneficiaries remains a top priority for Amniox. “
Amniox Medical is the only provider of a human tissue allograft composed of both umbilical cord and amniotic membrane. These tissues have innate regenerative properties that can be preserved and transplanted to other environments. Amniox utilizes its proprietary CRYOTEK process, a cryopreservation technology, to preserve the biological and structural integrity of these tissues. Published studies have demonstrated that the CRYOTEK process better preserves the structural integrity and biological signaling molecules of these tissues when compared to dehydrated tissues.
“Physicians will now have the opportunity to offer patients a wider variety of wound care treatment options for persons with chronic wounds,” said Dr. Wayne Caputo, Director of Wound Care Center, Clara Maass Medical Center/Saint Barnabas Health Care System, Belleville, NJ. “In my experience, the advantages of the Amniox technology have benefitted patients who failed to heal with other advanced wound care solutions, and in many cases have enabled me to avoid amputation or other radical measures.”
About Amniox Medical, Inc.
Founded in 2011 to serve the orthopedic and wound care markets, AMNIOX Medical is dedicated to developing and marketing regenerative therapies processed from amniotic membrane and umbilical cord matrix utilizing its proprietary CRYOTEK technology. This process has been proven to preserve the innate biological and structural properties of the matrix, which can then be transplanted to adult wound and surgical environments. AMNIOX Medical procures its tissue through elective donation following healthy live birth via Cesarean section. Thorough donor screening is performed to ensure the safety of its products. For additional information, please visit http://www.biotissue.com.
About TissueTech, Inc.
TissueTech, Inc. is a leader in regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal and wound care markets. The National Institutes of Health (NIH) has supported TissueTech’s research with more than 25 continuous years of research grants. Since inception, more than 170,000 human implants have been conducted using the Company’s patented CryoTek™ process and 300 peer-reviewed scientific publications have been produced supporting the technology platform. The Company has pioneered the clinical application of human amniotic membrane and its role in stem cell research. The Company’s first product, AmnioGraft®, is the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation.
For Amniox Medical, Inc.
Amy Phillips, 412-327-9499